Merck Shareholders' Vytorin Suit Settles For $5.1 Mil. in Fees

Settlement of a shareholders derivative suit over Merck & Co.'s alleged suppression of an unfavorable clinical study of its cholesterol drug Vytorin has won a federal judge's approval.
TheLegalIntelligencer.com

View this post on my blog: http://onlinefindlawyers.com/find-lawyers/merck-shareholders-vytorin-suit-settles-for-5-1-mil-in-fees.html